Chih-Hsin Yang - JoVE Visualize

Showing results (231-240 of 324) with videos related to

Pageof 33

Sort By:

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2011

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approachManuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, et al.

Investigational New Drugs|November 26, 2013

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsSharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLCJhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.

Japanese Journal of Clinical Oncology|December 5, 2006

Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in TaiwanReury-Perng Perng, Chih-Yi Chen, Gee-Chen Chang, et al.

Clinical and Translational Medicine|December 23, 2024

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.

Oncology|October 1, 2023

Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.

The New England Journal of Medicine|August 21, 2009

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.

The Lancet. Oncology|February 7, 2020

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.

Pageof 33

Showing results (231-240 of 324) with videos related to

Sort By:

Pageof 33

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2011

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approachManuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, et al.

Investigational New Drugs|November 26, 2013

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsSharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLCJhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.

Japanese Journal of Clinical Oncology|December 5, 2006

Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in TaiwanReury-Perng Perng, Chih-Yi Chen, Gee-Chen Chang, et al.

Clinical and Translational Medicine|December 23, 2024

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.

Oncology|October 1, 2023

Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.

The New England Journal of Medicine|August 21, 2009

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.

The Lancet. Oncology|February 7, 2020

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.

Pageof 33